Potential drug interactions among people living with HIV on antiretroviral therapy in Belo Horizonte, Brazil
DOI:
https://doi.org/10.30968/rbfhss.2024.153.1168Abstract
Objective: To characterize the medication use profile and evaluate the factors associated with serious and contraindicated potential drug-drug interactions (DDIs) in pharmacotherapy of people living with HIV (PLHIV). Method: This is a cross-sectional study, comprising two moments in the trajectory of PLHIV treatment - baseline and reevaluation. Sociodemographic, clinical and therapeutic variables were obtained from medical records and interviews. The medications used were classified using the Anatomical Therapeutic Chemical (ATC) system and potential DDIs were identified and classified according to the severity and quality of documentation using Micromedex®. Descriptive analyses were carried out to characterize the selected variables and the logistic regression method was used for univariate and multivariate analyses. Results: At baseline (n=247), the mean age was 36.8 years, with 60.3% being male. Potential DDIs were observed in 84.2% of participants. Upon the reevaluation (n=100), the mean age was 53.0 years, with a male majority (54.0%). Potential DDIs were observed in 63.8% of participants. There was a reduction in the proportion of anti-infectives and an increase in cardiovascular medications, when comparing the baseline and reevaluation. The number of medications (> 3) and the antiretroviral regimen remained associated with the occurrence of potential serious and contraindicated DDIs. Conclusion: The profile of medications used reflected the pattern of the most prevalent diseases in the periods evaluated. There was a reduction in the mean number of medications used and, consequently, a reduction in the number of DDIs at both moments, including those of greater severity.
Downloads
References
BRASIL. Ministério da Saúde: Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em adultos. Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Brasília/DF: Ministério da Saúde; 2023. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts. Acessado em: 08 de fevereiro de 2024.
BRASIL. Ministério da Saúde: Recomendações para terapia antirretroviral em adultos infectados pelo HIV. 7.ed. Brasília/DF: Ministério da Saúde; 2008. Disponível em: http://www.ensp.fiocruz.br/portal-ensp/judicializacao/pdfs/491.pdf. Acessado em: 08 de fevereiro de 2024.
Mendicino CCP, Silva GJ da, Braga LP, et al. Monitoring HIV infection in Minas Gerais state: 15-year assessment of adults living with HIV initiating Antiretroviral Therapy. Rev. Soc. Bras. Med. Trop. 2020;53(20200360). DOI: 10.1590/0037-8682-0360-2020.
INSIGHT START Study Group et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. DOI: 10.1056/NEJMoa1506816.
TEMPRANO Study Group et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808–22. DOI:10.1056/NEJMoa1507198.
Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2):171-181. DOI: 10.1001/jama.2016.5148.
World Health Organization. The role of HIV viral suppression in improving individual health and reducing transmission; 2023. Disponível em: https://www.who.int/publications/i/item/9789240055179. Acessado em: 08 de fevereiro de 2024.
de Sousa ACL, Eleuterio T de A, Coutinho JVA, et al. Assessing antiretroviral therapy success in HIV/AIDS morbidity and mortality trends in Brazil, 1990–2017: an interrupted time series study. Int J STD AIDS. 2021;32(2):127–34. DOI: 10.1177/0956462420952989.
Nakagawa F, May M, Phillips A. Life expectancy living with HIV. Curr Opin Infect Dis. 2013;26(1):17–25. DOI: 10.1097/QCO.0b013e32835ba6b1.
Smiley CL, Rebeiro PF, Cesar C, et al. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV. 2021;8(5):e266–273. DOI: 10.1016/S2352-3018(20)30358-1.
Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295–307. DOI: 10.1016/S2352-3018(23)00028-0.
Moya Y, Bernal F, Rojas E, et al. Seguimiento fármaco-terapéutico en pacientes ambulatorios con tratamiento anti-retroviral. Rev Chilena Infectol. 2012;29(4):412–419. DOI: 10.4067/S0716-10182012000400008.
Marinho F, de Azeredo Passos VM, Carvalho Malta D, et al. Burden of disease in Brazil, 1990–2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10149):760–775. DOI: 10.1016/ S0140-6736(18)31221-2.
Mendicino CCP, Moreira Costa AA, da Silva GJ, et al. Metabolic comorbidities and systemic arterial hypertension: the challenge faced by HIV patients on long-term use of antiretroviral therapy. Hosp Pract. 2022;50(1):75–81. DOI:10.1080/21548331.2022.2030564
World Health Organization. Medication safety in polypharmacy: technical report. 2019. Disponível em: https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11. Acessado em: 11 de março de 2024.
Halloran MO, Boyle C, Kehoe B, et al. Polypharmacy and drug–drug interactions in older and younger people living with HIV: the POPPY study. Antivir Ther. 2019;24(3):193–201. DOI: 10.3851/IMP3293.
Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Intern AIDS Soc. 2020;23(2):e25449. DOI: 10.1002/jia2.25449
Tinggaard M, David KP, Gerstoft J, et al. Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey. HIV Med. 2022;24(1):46-54. DOI: 10.1111/hiv.13321.
Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population. J Gen Intern Med. 2013;28(10):1302–1310. DOI:10.1007/s11606-013-2449-6.
Gimeno-Gracia M, Crusells-Canales MJ, Javier Armesto-Gómez F, et al. Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV Clin Trials. 2015;16(3):117–124. DOI: 10.1179/1528433614Z.0000000012.
World Health Organization. Medication Without Harm. 2017. Disponível em: https://www.who.int/publications/i/item/WHO-HIS-SDS-2017.6. Acessado em: 11 de março de 2024.
Menezes de Pádua CA, Moura CS. Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort. Clin Drug Investig. 2014;34(6):395–402. DOI:10.1007/s40261-014-0187-0.
World Health Organization. Índice ATC/DDD 2022. Geneva: World Health Organization, 2022. Disponível em: https://www.whocc.no/atc_ddd_index/. Acessado em: 11 de março de 2024.
Analytics Inc., T. H. Micromedex® Clinical Knowledge Suite. Micromedex Solutions - User guide. ANALYTICS INC., T. H. Michigan, USA 2021.
Balderson BH, Grothaus L, Harrison RG, et al. Chronic illness burden and quality of life in an aging HIV population. AIDS Care. 2012;25(4):451–8. DOI: 10.1080/09540121.2012.712669.
Deutschmann E, Bucher HC, Jaeckel S, et al. Prevalence of Potential Drug–Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. Clin Infect Dis. 2021;73(7):e2145–2152. DOI: 10.1093/cid/ciaa918.
Schouten J, Wit FW, Stolte IG, et al. Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study. Clin Infect Dis. 2014;59(12):1787–1797. DOI: 10.1093/cid/ciu701.
Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413–423. DOI: 10.3851/IMP1540.
Paudel M, Prajapati G, Buysman EK, et al. Comorbidity andcomedication burden among people living with HIV in the United States. Curr Med Res Opin. 2022;38(8):1443–1450. DOI: 10.1080/03007995.2022.2088714.
Siefried KJ, Mao L, Cysique LA, et al. Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS. 2018;32(1):35–48. DOI: 10.1097/QAD.0000000000001685.
Yesilbag Z, SengUl EI, Senoglu S, et al. Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors. Curr HIV Res. 2020;18(6):415–425. DOI: 10.2174/1574885515666200812215140.
BRASIL. Ministério da Saúde: Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em adultos. Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Brasília/DF: Ministério da Saúde; 2018. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/pcdts/2013/hiv-aids/pcdt_manejo_adulto_12_2018_web.pdf/view. Acessado em: 06 de março de 2024.
Ghosh AK. Four decades of continuing innovations in the development of antiretroviral therapy for HIV/AIDS: Progress to date and future challenges. Glob Health Med. 2023;5(4):194-198. DOI: 10.35772/ghm.2023.01013.
Katzung BG, Masters SB, Trevor AJ. Farmacologia Básica e Clínica, 12. ed. Porto Alegre: AMHG; 2014.
Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31(7):815–832. DOI: 10.1124/dmd.31.7.815.
Okoli C, Schwenk A, Radford M, et al. Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database. HIV Med. 2020;21(8):471–480. DOI: 10.1111/hiv.12879.
BRASIL. Ministério da Saúde: Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em adultos. Departamento de DST, Aids e Hepatites Virais. Brasília/DF: Ministério da Saúde; 2013. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_manejo_hiv_adultos.pdf. Acessado em: 13 de setembro de 2024.
Peng AT, Huang SH, Lee HY, et al. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2024;63(2):107067. DOI: 10.1016/j.ijantimicag.2023.107067.
Majdouline El Moussaoui, Lambert I, Maes N, et al. Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. Open Forum Infect Dis. 2020;7(11):ofaa416. DOI: 10.1093/ofid/ofaa416.
Pontelo BM, Greco DB, Guimarães NS, et al. Profile of drug–drug interactions and impact on the effectiveness of antiretroviral therapy among patients living with HIV followed at an Infectious Diseases Referral Center in Belo Horizonte, Brazil. Braz J Infect Dis. 2020;24(2):104–109. DOI: 10.1016/j.bjid.2020.03.006.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
